Inhibitors of the Proteolytic Activity of Urokinase Type Plasminogen Activator

Author(s): Todd W. Rockway, Vincent L. Giranda

Journal Name: Current Pharmaceutical Design

Volume 9 , Issue 19 , 2003

Become EABM
Become Reviewer
Call for Editor


Urokinase type plasminogen activator (uPA) activates plasminogen to plasmin and is often associated with diseases where tissue remodeling is essential (e.g. cancer, macular degeneration, atherosclerosis). We discuss some of the mechanisms of uPA action in diseases, and evidence that some of the early uPA inhibitors can modulate the progression of these diseases. Recently, a number of research groups have discovered, with the aid of structure-based design, a new generation of uPA inhibitors. These inhibitors are much more potent and selective than their predecessors. We will review this progress here, and give particular attention to the structural rationale associated with these observed increases in potency and selectivity.

Keywords: urokinase type plasminogen activator, upa inhibitors

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2003
Page: [1483 - 1498]
Pages: 16
DOI: 10.2174/1381612033454649
Price: $65

Article Metrics

PDF: 8